

CORRECTING and REPLACING: Erytech Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital

February 4, 2016 5:32 AM ET

December 2015

Article 223-16 of general regulation of French Autorité des Marchés Financiers

LYON, France--(BUSINESS WIRE)--Feb. 4, 2016-- Regulatory News:

This replaces the announcement made at 2:20 pm on January 12 due to the following corrections: The total of brut voting rights of 9 625 437 is superseded by 9 706 437 and the total of net voting rights of 9 622 937 is superseded by 9 703 937.

Erytech Pharma: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital

December 2015

Article 223-16 of general regulation of French Autorité des Marchés Financiers

Erytech Pharma (Paris:ERYP) (ADR:EYRYY):

Listing market : Euronext Paris from Euronext

Market segment : segment B

ISIN Code : FR0011471135

website : www.erytech.com

Date	Total of shares composing the share capital	Total of brut⁽¹⁾ voting rights	Total of net⁽²⁾ voting rights
31 January 2015	6 882 761	8 090 321	8 085 071
28 February 2015	6 886 441	8 094 001	8 092 501
31 March 2015	6 886 941	8 094 301	8 091 801
30 April 2015	6 888 441	8 043 911	8 041 411
06 May 2015	6 888 441	8 733 677 ⁽³⁾	8 731 177
31 May 2015	6 888 441	8 728 137	8 725 637
30 June 2015	6 889 291	8 675 087	8 672 587
31 July 2015	6 896 791	8 687 487	8 684 987
31 August 2015	6 901 641	8 686 137	8 683 637
30 September 2015	6 902 341	8 683 837	8 681 337
31 October 2015	6 903 041	8 684 412	8 681 912
30 November 2015	6 909 531	8 691 157	8 688 657
7 December 2015	7 849 531 ⁽⁴⁾	9 631 157	9 628 657
31 December 2015	7 924 611	9 706 437	9 703 937

(1) Gross voting rights number (or « theoretical » voting rights) is used as a calculus base for the crossing of the threshold. In accordance with article 223-11 of general regulation of Autorité des Marchés Financiers, this number is calculated on the basis of all shares carrying the single and double voting rights, including shares without voting rights.

(2) Without treasury shares

(3) The total number of voting rights raised significantly due to the acquisition of double voting rights related to shares

namely owned for more than two years.

(4) The total of shares composing the share capital has increased following the private placement under AMF Visa n°15-614.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160204005595/en/>

Source: Erytech Pharma

Erytech Pharma